Testing Shorter Chemo‑Immunotherapy Without Anthracycline Drugs for Early‑Stage Triple Negative Breast Cancer
Testing a shorter anthracycline‑free chemo‑immunotherapy regimen for early‑stage triple‑negative breast cancer.
Phase III clinical trial evaluating whether a shorter, anthracycline‑free chemo‑immunotherapy regimen (docetaxel + carboplatin + pembrolizumab) is as effective and less toxic than the standard anthracycline‑containing regimen (paclitaxel + carboplatin + doxorubicin + cyclophosphamide + pembrolizumab) for early‑stage triple‑negative breast cancer.
Reducing the number of chemotherapy agents may diminish side effects and improve patient tolerability while maintaining oncologic efficacy, potentially altering standard pre‑operative treatment for early‑stage triple‑negative breast cancer.
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.
Related signals
- 20‑Year Risks of Breast‑Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
- Breast Cancer: The good, the bad, and an important call to effective risk reduction strategies
- Clinical Trials in Cancer - Transforming Clinical Research in the United States - NCBI Bookshelf
- Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing
- The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21st century: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors - PMC